FDA puts clinical hold on Abeona’s Phase III study of EB-101
EB-101 is an investigational, autologous, gene-corrected cell therapy. Credit: Pete Linforth from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more